These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 38629072)

  • 1. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
    Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
    Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer.
    Wang Q; Zhong W; Shen X; Hao Z; Wan M; Yang X; An R; Zhu H; Cai H; Li T; Lv Y; Dong X; Chen G; Liu A; Du J
    NPJ Precis Oncol; 2024 Mar; 8(1):61. PubMed ID: 38431733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
    Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
    Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
    Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
    JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance.
    Zou X; Lin X; Cheng H; Chen Y; Wang R; Ma M; Liu Y; Dai Z; Tasiheng Y; Yan Y; Hou Q; Ding F; Chen H; Yu X; Wang X; Liu C
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
    Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 12. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 13. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic responders.
    Sidiropoulos DN; Shin SM; Wetzel M; Girgis AA; Bergman D; Danilova L; Perikala S; Shu DH; Montagne JM; Deshpande A; Leatherman J; Dequiedt L; Jacobs V; Ogurtsova A; Mo G; Yuan X; Lvovs D; Stein-O'Brien G; Yarchoan M; Zhu Q; Harper EI; Weeraratna AT; Kiemen AL; Jaffee EM; Zheng L; Ho WJ; Anders RA; Fertig EJ; Kagohara LT
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
    Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
    Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
    Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
    Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.
    Spear S; Candido JB; McDermott JR; Ghirelli C; Maniati E; Beers SA; Balkwill FR; Kocher HM; Capasso M
    Front Immunol; 2019; 10():542. PubMed ID: 30972056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
    Merali N; Jessel MD; Arbe-Barnes EH; Ruby Lee WY; Gismondi M; Chouari T; O'Brien JW; Patel B; Osei-Bordom D; Rockall TA; Sivakumar S; Annels N; Frampton AE
    HPB (Oxford); 2024 Jul; 26(7):873-894. PubMed ID: 38729813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
    Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H
    Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.